Skip to main content
SpringerLink
Log in
Book cover

Malignant Mesothelioma pp 416–429Cite as

Prognostic Factors in Mesothelioma

  • Chapter

  • 949 Accesses

Conclusion

Patients with good and poor prognosis can now be determined by well-validated prognostic factors based on the EORTC and CALGB scoring systems. These distinct, but closely related systems, have clarified much contradictory data accrued over the past two decades. The most important poor prognosis predictors are poor performance status, nonepithelial histology, male gender, low hemoglobin, high platelet count, high white blood cell count, and high LDH. In addition to prognostic information these systems have led to insights into the biology of mesothelioma, in particular, the possible role played by cytokine networks in the symptoms experienced by patients with mesothelioma. Prognostic factors may, at last, not simply enable us to predict a worse outcome for some patients compared to others, but help us understand mesothelioma and develop new treatments. Numerous molecular biologic markers of prognosis are under investigation. Overexpression of various cellular proteins has been demonstrated to correlate with the clinical outcome in the source patients. Understanding the importance of these markers in predicting prognosis will lead to better understanding of malignant mesothelioma and will help improve therapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Steele JP, Rudd RM. Malignant mesothelioma: predictors of prognosis and clinical trials. Thorax 2000;55:725–726.

    Article  PubMed  CAS  Google Scholar 

  2. Edwards JG, Faux SP, Plummer SM, et al. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. Clin Cancer Res 2002;8:1857–1862.

    PubMed  CAS  Google Scholar 

  3. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the cancer and Leukemia Group B. Chest 1998;113:723–731.

    PubMed  CAS  Google Scholar 

  4. Curran D, Sahmoud T, Therasse, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145–152.

    PubMed  CAS  Google Scholar 

  5. Middleton GW, Smith IE, O’Brien ME. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269–273.

    Article  PubMed  CAS  Google Scholar 

  6. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25–30.

    PubMed  CAS  Google Scholar 

  7. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912–3917.

    PubMed  CAS  Google Scholar 

  8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644.

    Article  PubMed  CAS  Google Scholar 

  9. Cox DR. Regression models and life-tables. J R Stat Soc 1972;B34:187–202.

    Google Scholar 

  10. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Cancer 1993;72:394–404.

    Article  PubMed  CAS  Google Scholar 

  11. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and Adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987;5:86–91.

    PubMed  CAS  Google Scholar 

  12. Tammilehto L. Malignant mesothelioma: prognostic factors in a prospective study of 9 patients. Lung Cancer 1992;8:175–184.

    Article  Google Scholar 

  13. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant mesothelioma. J Thorac Cardiovasc Surg 1991;102:1–9.

    PubMed  CAS  Google Scholar 

  14. Chahinian AP, Pajak TF, Holland JF. Diffuse malignant mesothelioma. Ann Intern Med 1982;96:746–755.

    PubMed  CAS  Google Scholar 

  15. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 188 consecutive patients. Cancer 1993;72:410–417.

    Article  Google Scholar 

  16. De Pangher Manzini V, Brollo A, et al. Prognostic factors of malignant mesothelioma of the pleura. Cancer 1993;72:410–417.

    Article  PubMed  Google Scholar 

  17. Antman KH, Shemin R, Ryan L. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988;6:147–153.

    PubMed  CAS  Google Scholar 

  18. Calavrezos A, Koschel G, Husselman H, et al. Malignant mesothelioma of the pleura. Klin Wochenschr 1988;66:607–613.

    Article  PubMed  CAS  Google Scholar 

  19. Spirtas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525–530.

    PubMed  CAS  Google Scholar 

  20. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799–1804.

    Article  PubMed  CAS  Google Scholar 

  21. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54–63.

    Article  PubMed  CAS  Google Scholar 

  22. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. Lung Cancer 2003;41(suppl 2):S12.

    Article  Google Scholar 

  23. Edwards JG, Abrams KR, Leverment JN, et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000;55:731–735.

    Article  PubMed  CAS  Google Scholar 

  24. Neumann V, Rutten A, Scharmach M, Muller KM, Fischer M. Factors influencing long-term survival in mesothelioma patients-results of the German Mesothelioma Register. Int Arch Occup Environ Health, 2004; Feb 27.

    Google Scholar 

  25. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 1995;12:455–460.

    PubMed  CAS  Google Scholar 

  26. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761–3764.

    PubMed  CAS  Google Scholar 

  27. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455–460.

    Article  PubMed  CAS  Google Scholar 

  28. Sheehan KM, Sheahan K, O’Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999;282:1254–1257.

    Article  PubMed  CAS  Google Scholar 

  29. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000;6:4739–4744.

    PubMed  CAS  Google Scholar 

  30. Beer TW, Shepherd P, Pullinger NC. p27 immunostaining is related to prognosis in malignant mesothelioma. Histopathology 2001;38:535–541.

    Article  PubMed  CAS  Google Scholar 

  31. Bongiovanni M, Cassoni P, De Giuli P, et al. p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 2001;92:1245–1250.

    Article  PubMed  CAS  Google Scholar 

  32. Comin CE, Anichini C, Boddi V, Novelli L, Dini S. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000;36:26–31.

    Article  PubMed  CAS  Google Scholar 

  33. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and-2, and TGF beta expression. J Pathol 1999;189:72–78.

    Article  PubMed  CAS  Google Scholar 

  34. Ohta Y, Shridar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81:54–61.

    Article  PubMed  CAS  Google Scholar 

  35. Strizzi L, Muraro R, Vianale G, et al. Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol 2002;197:218–223.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mesothelioma Unit, St. Bartholomew’s Hospital and Medical College, London, UK

    Jeremy P. C. Steele MD

  2. Department of Medical Oncology, St. Bartholomew’s Hospital and Medical College, London, UK

    Dean A. Fennell

Authors
  1. Jeremy P. C. Steele MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dean A. Fennell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Harper University Hospital, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  2. Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  3. Nevada Cancer Institute, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  4. Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 81935, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  5. Thoracic Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 60153, USA

    Michele Carbone MD, PhD (Professor of Pathology, Director) (Professor of Pathology, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Steele, J.P.C., Fennell, D.A. (2005). Prognostic Factors in Mesothelioma. In: Pass, H.I., Vogelzang, N.J., Carbone, M. (eds) Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/0-387-28274-2_27

Download citation

  • DOI: https://doi.org/10.1007/0-387-28274-2_27

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22949-2

  • Online ISBN: 978-0-387-28274-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation